SCINAI IMMUNOTHERAPEUTICS LTD. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 413.20 million shares for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-04-01
- SCINAI IMMUNOTHERAPEUTICS LTD. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 28.92M shares, a 0.10% increase from fiscal 2021.
- SCINAI IMMUNOTHERAPEUTICS LTD. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 28.89M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|
| 2025-12-31 | 413.20M shares 20-F · filed 2026-04-01 |
| 2023-12-31 | 97.55M shares 20-F · filed 2024-05-15 |
| 2022-12-31 | 28.92M shares 10-K · filed 2023-04-17 |
| 2021-12-31 | 28.89M shares 10-K · filed 2023-04-17 |